Efficacy and safety of rituximab therapy for refractory/relapsing thrombotic thrombocytopenic purpura / 中国医学科学院学报
Zhongguo yi xue ke xue yuan xue bao
; Zhongguo yi xue ke xue yuan xue bao;(6): 116-120, 2013.
Article
en Zh
| WPRIM
| ID: wpr-284295
Biblioteca responsable:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the efficacy and safety of rituximab in treating patients with refractory and/or relapsing thrombotic thrombocytopenic purpura (TTP).</p><p><b>METHODS</b>Totally three patients received rituximab as salvage therapy in our hospital. Rituximab was administered at a weekly dose of 375 mg/m(2) for 2 or 4 consecutive weeks. After clinical remission, patients were followed up every 3 months.</p><p><b>RESULTS</b>All three patients achieved complete remission. The median time to platelet count recovery was 7 days (4-12 days) after the first rituximab infusion. During the follow-up (median: 12 months; range: 9-18 months), no patients experienced relapse. No side effect was noted during treatment and follow-up period.</p><p><b>CONCLUSION</b>Therapy with rituximab is effective and well tolerated for patients with refractory or relapsing TTP.</p>
Texto completo:
1
Base de datos:
WPRIM
Asunto principal:
Púrpura Trombocitopénica Trombótica
/
Estudios Retrospectivos
/
Resultado del Tratamiento
/
Terapia Recuperativa
/
Usos Terapéuticos
/
Quimioterapia
/
Anticuerpos Monoclonales de Origen Murino
/
Rituximab
Tipo de estudio:
Observational_studies
Límite:
Adult
/
Aged
/
Female
/
Humans
Idioma:
Zh
Revista:
Zhongguo yi xue ke xue yuan xue bao
Año:
2013
Tipo del documento:
Article